Renal Autologous Cell Therapy in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis

Overview of attention for article published in Blood Purification, January 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#6 of 894)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 16 news outlets
twitter: 7 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 31 Mendeley

Summary News X Facebook Dimensions citations

So far, Dimensions has found 1 citation of this research output.

1

The most recent citing publication is shown below. View this citation on Dimensions.

Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and Type 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Redosing Triggers

Article in American Journal of Nephrology (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.